Sign up to save your podcasts
Or
Share SOC 204: Media or Medicine - GLP-1s
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
SOC 204: Media or Medicine - GLP-1s
With groundbreaking medical advancements and the the rise of fatphobia and intolerance, GLP-1s feel like the awkward elephant in the room. This infamous medication has bounced around Super Bowl commercials and social media advertisements, leaving a trail of hot takes and misinformation. Today, Ilyana and Gold explain the real function of the drug and discuss the historical background of weight marginalization and the social implications of GLP-1 medications. Get settled, it’s a long one.
Listen To Us Anywhere:
YouTube: https://www.youtube.com/channel/UC5Bf6Gk-SuKnWK0zI0i3M3Q
Contact Us: [email protected]
Music: William Pleasant
Design: Matheus Lago
Required Reading:
GLP-1 Agonists: What They Are, How They Work & Side Effects
GLP-1 and health: Beyond weight loss in the Ozempic era
How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond - Harvard Health
New GLP-1 weight-loss drugs are coming—and they’re stronger than Wegovy and Zepbound | Scientific American
GLP-1 obesity drugs and eating disorders are not well understood yet : NPR
Comparing the Impact of GLP-1 Agonists vs. Lifestyle Interventions and Weight Controllability Information on Stigma and Weight-Related Cognitions | International Journal of Behavioral Medicine | Springer Nature Link
WHO issues global guideline on the use of GLP-1 medicines in treating obesity
Addressing weight bias in medicine - Harvard Health
Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more
KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs
Where does fat phobia come from?
The History and Faults of the Body Mass Index and Where to Look Next: A Literature Review
The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity
Dangers and Opportunities of Direct-to-Consumer Advertising
Impact of weight bias and stigma on quality of care and outcomes for patients with obesity
Opinion Pieces:
I’ve Had 2 Weight-Loss Surgeries And Now I’m On Wegovy. None Of It Made Me Any Healthier. | HuffPost HuffPost Personal
#stem #glp1 #fatphobia #research #medicine
View all episodes
By IB and GCWith groundbreaking medical advancements and the the rise of fatphobia and intolerance, GLP-1s feel like the awkward elephant in the room. This infamous medication has bounced around Super Bowl commercials and social media advertisements, leaving a trail of hot takes and misinformation. Today, Ilyana and Gold explain the real function of the drug and discuss the historical background of weight marginalization and the social implications of GLP-1 medications. Get settled, it’s a long one.
Listen To Us Anywhere:
YouTube: https://www.youtube.com/channel/UC5Bf6Gk-SuKnWK0zI0i3M3Q
Contact Us: [email protected]
Music: William Pleasant
Design: Matheus Lago
Required Reading:
GLP-1 Agonists: What They Are, How They Work & Side Effects
GLP-1 and health: Beyond weight loss in the Ozempic era
How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond - Harvard Health
New GLP-1 weight-loss drugs are coming—and they’re stronger than Wegovy and Zepbound | Scientific American
GLP-1 obesity drugs and eating disorders are not well understood yet : NPR
Comparing the Impact of GLP-1 Agonists vs. Lifestyle Interventions and Weight Controllability Information on Stigma and Weight-Related Cognitions | International Journal of Behavioral Medicine | Springer Nature Link
WHO issues global guideline on the use of GLP-1 medicines in treating obesity
Addressing weight bias in medicine - Harvard Health
Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more
KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs
Where does fat phobia come from?
The History and Faults of the Body Mass Index and Where to Look Next: A Literature Review
The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity
Dangers and Opportunities of Direct-to-Consumer Advertising
Impact of weight bias and stigma on quality of care and outcomes for patients with obesity
Opinion Pieces:
I’ve Had 2 Weight-Loss Surgeries And Now I’m On Wegovy. None Of It Made Me Any Healthier. | HuffPost HuffPost Personal
#stem #glp1 #fatphobia #research #medicine